Related Articles
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer
Alternate‑day administration of S‑1 for elderly patients with advanced non‑small‑cell lung carcinoma: A prospective feasibility study
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients